Anvisa publishes resolution to expand access to medicines related to Covid-19

In order to mitigate the impacts of Covid-19 and avoid product shortages, Anvisa, in partnership with INTERFARMA and other pharmaceutical industry associations, developed a new Resolution (RDC #348/2020) published on March 18th.

The resolution includes exceptional criteria and procedures to speed up the registration and post-registration of medicines, biological products and laboratory diagnosis (in vitro) to prevent and treat the Coronavirus disease. The measure has already resulted in the approval of eight new tests for professional use for diagnosis and screening of the disease.